• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Depression - Pipeline Review, H2 2012 Product Image

Depression - Pipeline Review, H2 2012

  • Published: October 2012
  • 510 pages
  • Global Markets Direct

Depression – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Depression - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Depression, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Depression. Depression - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Depression.
- A review of the Depression products under development by companies and universities/research institutes based on information derived from company READ MORE >

2
List of Tables 25
List of Figures 28
Introduction 29
REPORT COVERAGE 29
Depression Overview 30
Therapeutics Development 31
An Overview of Pipeline Products for Depression 31
Depression Therapeutics under Development by Companies 33
Depression Therapeutics under Investigation by Universities/Institutes 41
Late Stage Products 47
Comparative Analysis 47
Mid Clinical Stage Products 48
Comparative Analysis 48
Early Clinical Stage Products 49
Comparative Analysis 49
Discovery and Pre-Clinical Stage Products 50
Comparative Analysis 50
Depression Therapeutics – Products under Development by Companies 51
Depression Therapeutics – Products under Investigation by Universities/Institutes 60
Companies Involved in Depression Therapeutics Development 65
Bristol-Myers Squibb Company 65
F. Hoffmann-La Roche Ltd. 66
Abbott Laboratories 67
AstraZeneca PLC 68
Eli Lilly and Company 69
Alkermes, Inc. 70
Merck & Co., Inc. 71
Dainippon Sumitomo Pharma Co., Ltd. 72
Taisho Pharmaceutical Co., Ltd. 73
Otsuka Pharmaceutical Co., Ltd. 74
Takeda Pharmaceutical Company Limited 75
Alexza Pharmaceuticals, Inc. 76
Zogenix, Inc. 77
Aphios Corporation 78
Astellas Pharma Inc. 79
Eisai Co., Ltd. 80
Elan Corporation, plc 81
Gedeon Richter Plc. 82
H Lundbeck A/S 83
Pfizer Inc. 84
Sigma-Tau S.p.A. 85
Teva Pharmaceutical Industries Limited 86
Sun Pharmaceutical Industries Limited 87
Shire Plc 88
NuPathe Inc. 89
Addex Pharmaceuticals 90
FAES Farma SA 91
Anavex Life Sciences Corp. 92
Neuralstem, Inc. 93
IntelGenx Technologies Corp. 94
Karo Bio 95
Neuren Pharmaceuticals Limited 96
NeuroSearch A/S 97
Corcept Therapeutics Incorporated 98
Repligen Corporation 99
Suven Life Sciences Ltd. 100
e-Therapeutics plc 101
Rexahn Pharmaceuticals, Inc. 102
Intas Pharmaceuticals Ltd. 103
M et P Pharma AG 104
Angelini Group 105
D-Pharm Ltd. 106
Avanti Therapeutics 107
Domain Therapeutics 108
Ironwood Pharmaceuticals, Inc. 109
Abiogen Pharma S.p.A. 110
Indena S.p.A. 111
Affectis Pharmaceuticals AG 112
Trevena, Inc. 113
Supernus Pharmaceuticals, Inc. 114
Psylin Neurosciences, Inc. 115
Pantarhei Bioscience BV 116
Ferrer Internacional S.A. 117
Indus Biotech Private Limited 118
Theracos, Inc. 119
NeuroNascent, Inc. 120
Azevan Pharmaceuticals, Inc. 121
CeNeRx BioPharma, Inc. 122
Concert Pharmaceuticals, Inc. 123
Dart NeuroScience LLC 124
Omeros Corporation 125
Targacept, Inc. 126
Ortho-McNeil Pharmaceuticals, Inc. 127
Vanda Pharmaceuticals Inc. 128
Marinus Pharmaceuticals, Inc. 129
M's Science Corporation 130
BrainCells Inc. 131
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 132
Cannasat Therapeutics, Inc. 133
Pierre Fabre Medicament 134
Lee's Pharmaceutical Holdings Limited 135
KemPharm, Inc. 136
Heptares Therapeutics Ltd. 137
Ascendis Pharma A/S 138
ArmaGen Technologies, Inc. 139
Pherin Pharmaceuticals, Inc. 140
Beech Tree Labs, Inc. 141
Reviva Pharmaceuticals Inc. 142
Mayne Pharma Limited 143
Mt Cook Pharma. Inc. 144
FunZyme BioTechnologies S.A. 145
Naurex, Inc. 146
PharmaNeuroBoost N.V. 147
Depression – Therapeutics Assessment 148
Assessment by Monotherapy Products 148
Assessment by Combination Products 149
Assessment by Route of Administration 150
Assessment by Molecule Type 152
Drug Profiles 155
scyllo-inositol - Drug Profile 155
Product Description 155
Mechanism of Action 155
R&D Progress 155
ANAVEX-1-41 - Drug Profile 157
Product Description 157
Mechanism of Action 157
R&D Progress 157
tedatioxetine - Drug Profile 158
Product Description 158
Mechanism of Action 158
R&D Progress 158
tedatioxetine - Drug Profile 160
Product Description 160
Mechanism of Action 160
R&D Progress 160
vortioxetine - Drug Profile 162
Product Description 162
Mechanism of Action 162
R&D Progress 162
F-98214-TA - Drug Profile 188
Product Description 188
Mechanism of Action 188
R&D Progress 188
Hyperforin - Drug Profile 189
Product Description 189
Mechanism of Action 189
R&D Progress 189
progesterone - Drug Profile 190
Product Description 190
Mechanism of Action 190
R&D Progress 190
Pioglitazone + Citalopram + Chlordiazepoxide - Drug Profile 287
Product Description 287
Mechanism of Action 287
R&D Progress 287
lisdexamfetamine dimesylate - Drug Profile 288
Product Description 288
Mechanism of Action 288
R&D Progress 288
ABT-436 - Drug Profile 291
Product Description 291
Mechanism of Action 291
R&D Progress 291
fluoxetine - Drug Profile 292
Product Description 292
Mechanism of Action 292
R&D Progress 292
escitalopram oxalate - Drug Profile 383
Product Description 383
Mechanism of Action 383
R&D Progress 383
TC-5214 + SSRI - Drug Profile 384
Product Description 384
Mechanism of Action 384
R&D Progress 384
citalopram hydrobromide - Drug Profile 421
Product Description 421
Mechanism of Action 421
R&D Progress 421
NLF-NEU - Drug Profile 422
Product Description 422
Mechanism of Action 422
R&D Progress 422
NRX-1074 - Drug Profile 423
Product Description 423
Mechanism of Action 423
R&D Progress 423
JRP-362 - Drug Profile 424
Product Description 424
Mechanism of Action 424
R&D Progress 424
JRP-227 - Drug Profile 425
Product Description 425
Mechanism of Action 425
R&D Progress 425
ELND-005+ Lamotrigine+ Valproic acid - Drug Profile 426
Product Description 426
Mechanism of Action 426
R&D Progress 426
minocycline - Drug Profile 428
Product Description 428
Mechanism of Action 428
R&D Progress 428
Depression Therapeutics – Drug Profile Updates 429
Depression Therapeutics – Discontinued Products 477
Depression Therapeutics - Dormant Products 485
Depression – Product Development Milestones 501
Featured News & Press Releases 501
Oct 02, 2012: Addex Therapeutics And Collaborators Receive CHF700,000 Grant To Develop Allosteric Modulators For Neurodegenerative And Psychiatric Diseases 501
Oct 02, 2012: Takeda And Lundbeck Announce US Submission Of NDA For Vortioxetine For Treatment Of Major Depressive Disorder 501
Sep 27, 2012: Forest Labs Submits New Drug Application For Levomilnacipran For Treatment Of Major Depressive Disorder 502
Sep 20, 2012: Lundbeck Files For Regulatory Approval Of New Multimodal Antidepressant Vortioxetine In Europe 503
Sep 17, 2012: Addex Partner Doses First Patient In Phase II Clinical Study Of ADX71149 For Treatment Of Major Depressive Disorder Patients With Anxiety Symptoms 504
Sep 06, 2012: Sunovion Pharma Files Two Supplemental New Drug Applications Seeking Approval For Use Of Latuda As Monotherapy And Adjunctive Therapy 504
Sep 03, 2012: Otsuka Pharma Files Additional Indication Application For Abilify For Treatment Of Depression 505
Aug 30, 2012: Janssen Pharma Announces Risperdal Consumer Protection Settlement With 36 States And District Of Columbia 506
Aug 30, 2012: Transition Therapeutics Announces Dosing Of First Patient In Phase II Clinical Study Of ELND005 In Bipolar Disorder 506
Aug 29, 2012: Elan Doses First Patient In Phase II Trial Of ELND005 In Bipolar Disorder 507
Appendix 508
Methodology 508
Coverage 508
Secondary Research 508
Primary Research 508
Expert Panel Validation 508
Contact Us 509
Disclaimer 509

List of Tables
Number of Products Under Development for Depression, H2 2012 31
Products under Development for Depression – Comparative Analysis, H2 2012 32
Number of Products under Development by Companies, H2 2012 34
Number of Products under Development by Companies, H2 2012 (Contd..1) 35
Number of Products under Development by Companies, H2 2012 (Contd..2) 36
Number of Products under Development by Companies, H2 2012 (Contd..3) 37
Number of Products under Development by Companies, H2 2012 (Contd..4) 38
Number of Products under Development by Companies, H2 2012 (Contd..5) 39
Number of Products under Development by Companies, H2 2012 (Contd..6) 40
Number of Products under Investigation by Universities/Institutes, H2 2012 42
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 43
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 44
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 45
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 46
Comparative Analysis by Late Stage Development, H2 2012 47
Comparative Analysis by Mid Clinical Stage Development, H2 2012 48
Comparative Analysis by Early Clinical Stage Development, H2 2012 49
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 50
Products under Development by Companies, H2 2012 51
Products under Development by Companies, H2 2012 (Contd..1) 52
Products under Development by Companies, H2 2012 (Contd..2) 53
Products under Development by Companies, H2 2012 (Contd..3) 54
Products under Development by Companies, H2 2012 (Contd..4) 55
Products under Development by Companies, H2 2012 (Contd..5) 56
Products under Development by Companies, H2 2012 (Contd..6) 57
Products under Development by Companies, H2 2012 (Contd..7) 58
Products under Development by Companies, H2 2012 (Contd..8) 59
Products under Investigation by Universities/Institutes, H2 2012 60
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 61
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 62
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 63
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 64
Bristol-Myers Squibb Company, H2 2012 65
F. Hoffmann-La Roche Ltd., H2 2012 66
Abbott Laboratories, H2 2012 67
AstraZeneca PLC, H2 2012 68
Eli Lilly and Company, H2 2012 69
Alkermes, Inc., H2 2012 70
Merck & Co., Inc., H2 2012 71
Dainippon Sumitomo Pharma Co., Ltd., H2 2012 72
Taisho Pharmaceutical Co., Ltd., H2 2012 73
Otsuka Pharmaceutical Co., Ltd., H2 2012 74
Takeda Pharmaceutical Company Limited, H2 2012 75
Alexza Pharmaceuticals, Inc., H2 2012 76
Zogenix, Inc., H2 2012 77
Aphios Corporation, H2 2012 78
Astellas Pharma Inc., H2 2012 79
Eisai Co., Ltd., H2 2012 80
Elan Corporation, plc, H2 2012 81
Gedeon Richter Plc., H2 2012 82
H Lundbeck A/S, H2 2012 83
Pfizer Inc., H2 2012 84
Sigma-Tau S.p.A., H2 2012 85
Teva Pharmaceutical Industries Limited, H2 2012 86
Sun Pharmaceutical Industries Limited, H2 2012 87
Shire Plc, H2 2012 88
NuPathe Inc., H2 2012 89
Addex Pharmaceuticals, H2 2012 90
FAES Farma SA, H2 2012 91
Anavex Life Sciences Corp., H2 2012 92
Neuralstem, Inc., H2 2012 93
IntelGenx Technologies Corp., H2 2012 94
Karo Bio, H2 2012 95
Neuren Pharmaceuticals Limited, H2 2012 96
NeuroSearch A/S, H2 2012 97
Corcept Therapeutics Incorporated, H2 2012 98
Repligen Corporation, H2 2012 99
Suven Life Sciences Ltd., H2 2012 100
e-Therapeutics plc, H2 2012 101
Rexahn Pharmaceuticals, Inc., H2 2012 102
Intas Pharmaceuticals Ltd., H2 2012 103
M et P Pharma AG, H2 2012 104
Angelini Group, H2 2012 105
D-Pharm Ltd., H2 2012 106
Avanti Therapeutics, H2 2012 107
Domain Therapeutics, H2 2012 108
Ironwood Pharmaceuticals, Inc., H2 2012 109
Abiogen Pharma S.p.A., H2 2012 110
Indena S.p.A., H2 2012 111
Affectis Pharmaceuticals AG, H2 2012 112
Trevena, Inc., H2 2012 113
Supernus Pharmaceuticals, Inc., H2 2012 114
Psylin Neurosciences, Inc., H2 2012 115
Pantarhei Bioscience BV, H2 2012 116
Ferrer Internacional S.A., H2 2012 117
Indus Biotech Private Limited, H2 2012 118
Theracos, Inc., H2 2012 119
NeuroNascent, Inc., H2 2012 120
Azevan Pharmaceuticals, Inc., H2 2012 121
CeNeRx BioPharma, Inc., H2 2012 122
Concert Pharmaceuticals, Inc., H2 2012 123
Dart NeuroScience LLC, H2 2012 124
Omeros Corporation, H2 2012 125
Targacept, Inc., H2 2012 126
Ortho-McNeil Pharmaceuticals, Inc., H2 2012 127
Vanda Pharmaceuticals Inc., H2 2012 128
Marinus Pharmaceuticals, Inc., H2 2012 129
M's Science Corporation, H2 2012 130
BrainCells Inc., H2 2012 131
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., H2 2012 132
Cannasat Therapeutics, Inc., H2 2012 133
Pierre Fabre Medicament, H2 2012 134
Lee's Pharmaceutical Holdings Limited, H2 2012 135
KemPharm, Inc., H2 2012 136
Heptares Therapeutics Ltd., H2 2012 137
Ascendis Pharma A/S, H2 2012 138
ArmaGen Technologies, Inc., H2 2012 139
Pherin Pharmaceuticals, Inc., H2 2012 140
Beech Tree Labs, Inc., H2 2012 141
Reviva Pharmaceuticals Inc., H2 2012 142
Mayne Pharma Limited, H2 2012 143
Mt Cook Pharma. Inc., H2 2012 144
FunZyme BioTechnologies S.A., H2 2012 145
Naurex, Inc., H2 2012 146
PharmaNeuroBoost N.V., H2 2012 147
Assessment by Monotherapy Products, H2 2012 148
Assessment by Combination Products, H2 2012 149
Assessment by Stage and Route of Administration, H2 2012 151
Assessment by Stage and Molecule Type, H2 2012 154
Depression Therapeutics – Drug Profile Updates 429
Depression Therapeutics – Discontinued Products 477
Depression Therapeutics – Discontinued Products (Contd..1) 478
Depression Therapeutics – Discontinued Products (Contd..2) 479
Depression Therapeutics – Discontinued Products (Contd..3) 480
Depression Therapeutics – Discontinued Products (Contd..4) 481
Depression Therapeutics – Discontinued Products (Contd..5) 482
Depression Therapeutics – Discontinued Products (Contd..6) 483
Depression Therapeutics – Discontinued Products (Contd..7) 484
Depression Therapeutics – Dormant Products 485
Depression Therapeutics – Dormant Products (Contd..1) 486
Depression Therapeutics – Dormant Products (Contd..2) 487
Depression Therapeutics – Dormant Products (Contd..3) 488
Depression Therapeutics – Dormant Products (Contd..4) 489
Depression Therapeutics – Dormant Products (Contd..5) 490
Depression Therapeutics – Dormant Products (Contd..6) 491
Depression Therapeutics – Dormant Products (Contd..7) 492
Depression Therapeutics – Dormant Products (Contd..8) 493
Depression Therapeutics – Dormant Products (Contd..9) 494
Depression Therapeutics – Dormant Products (Contd..10) 495
Depression Therapeutics – Dormant Products (Contd..11) 496
Depression Therapeutics – Dormant Products (Contd..12) 497
Depression Therapeutics – Dormant Products (Contd..13) 498
Depression Therapeutics – Dormant Products (Contd..14) 499
Depression Therapeutics – Dormant Products (Contd..15) 500

List of Figures
Number of Products under Development for Depression, H2 2012 31
Products under Development for Depression – Comparative Analysis, H2 2012 32
Products under Development by Companies, H2 2012 33
Products under Investigation by Universities/Institutes, H2 2012 41
Late Stage Products, H2 2012 47
Mid Clinical Stage Products, H2 2012 48
Early Clinical Stage Products, H2 2012 49
Discovery and Pre-Clinical Stage Products, H2 2012 50
Assessment by Monotherapy Products, H2 2012 148
Assessment by Combination Products, H2 2012 149
Assessment by Route of Administration, H2 2012 150
Assessment by Stage and Route of Administration, H2 2012 151
Assessment by Molecule Type, H2 2012 152
Assessment by Stage and Molecule Type, H2 2012 153

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos